Hikma Pharmaceuticals plc (LSE: HIK; ADR: HKMPY), commonly called Hikma, is a multinational pharmaceutical company headquartered in London, England. It was founded in 1978 in Amman, Jordan by Samih Darwazah and is publicly listed on the London Stock Exchange (the PLC entity was incorporated in the UK in 2005). Public sources place headcount at roughly 9,000–9,600 employees, with revenue of about US$3.1 billion in 2024 and roughly US$3.3 billion in 2025; market capitalization has recently been reported at approximately £2.9–3.1 billion. Ownership is widely held, with founder-linked holdings and institutional investors among the largest shareholders.
Hikma develops, manufactures, and markets generic, branded, and injectable pharmaceutical products. Its business is organized around three segments — Injectables, Generics, and Branded — spanning the United States, Europe, the Middle East and North Africa. It is a genuine operating company, not a patent assertion entity: it sells finished prescription medicines and supplies hospitals and pharmacies, and it holds regulatory approvals (including ANDAs) rather than a licensing-only portfolio.
Its litigation posture in the tracked data is exclusively defensive: 0 cases as plaintiff, 1 as defendant, in the Middle District of Florida. That case, Blue Cross & Blue Shield of Florida, Inc. v. Jazz Pharmaceuticals, Inc. et al. (M.D. Fla., filed 2023-12-11), is an antitrust/consumer-protection action, not a patent-infringement suit. Hikma appears as a co-defendant alongside Jazz and other generic manufacturers.
The Florida Blue case concerns Xyrem (sodium oxybate), Jazz's narcolepsy drug, and alleges a scheme to suppress generic competition — including sham patent litigation, REMS manipulation, and a "reverse payment" settlement between Jazz and Hikma (which acquired Roxane Laboratories). Plaintiffs, a Florida health insurer and its HMO affiliate, seek damages for alleged overcharges. Related Xyrem antitrust claims have proceeded in the consolidated In re Xyrem (Sodium Oxybate) Antitrust Litigation in the N.D. Cal. No merits findings are asserted here.